Weiling Medical

Weiling Medical (微灵医疗) is a Shenzhen-based company working on implantable brain-computer interfaces for serious medical use, building full-stack in-house capabilities across neural signal acquisition, hardware circuits, and AI decoding . Rather than the consumer-grade interaction products that dominate the sector, it targets severe brain injury — patients with disorders of consciousness, paralysis, or loss of speech — with a "diagnose first, then treat" approach combining two product pipelines spanning assisted diagnosis and repair-or-replace therapy, and it has completed China's first fully implantable BCI system surgery in a patient with a disorder of consciousness . Its team draws on researchers from leading international BCI institutions and collaborates with the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences . On funding, BlueRun Ventures and CDH co-led its angel round — BlueRun's managing director Rong Jing called it an internationally leading team with full-chain proprietary minimally invasive implantable BCI technology — Gaorong Ventures led its angel-plus round in 2023 , and most recently it raised over RMB 100 million led by Junzhong Capital to push clinical validation, device registration, and manufacturing build-out .